- Home
- ACB vs ANTX Comparison
ACB vs ANTX Comparison
Compare ACB & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | ANTX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.3M | 170.6M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ACB | ANTX |
|---|---|---|
| Price | $3.54 | $4.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 1.4M | 310.6K |
| Earning Date | 06-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $1.00 |
| 52 Week High | $6.67 | $6.91 |
Technical Indicators
Market Signals| Indicator | ACB | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 66.34 |
| Support Level | $3.22 | $1.06 |
| Resistance Level | $3.91 | $5.11 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 33.33 | 75.44 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.